Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Sequential Tislelizumab as Adjuvant Therapy in HCC
NCT04981665Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04981665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981665.